Nai-Kong V Cheung

USPTO Granted Patents = 49 (Patent Applications = 34)

CIPO Patents = 8 (Patent Applications = 25)

EPO Patents = 12 (Patent Applications = 33)

Average Co-Inventor Count = 1.9

ph-index = 11

Forward Citations = 364(Granted Patents)

Location History:

Cleveland, OH (US) (1985)
Purchase, NY (US) (2002 - 2023)
New York, NY (US) (2012 - 2024)

Company Filing History:

26 out of 560

Memorial Sloan Kettering Cancer Center

patents

21 out of 512

Sloan-kettering Institute for Cancer Research

patents

4 out of 48

Eureka Therapeutics, Inc.

Massachusetts Institute of Technology

patents

6. 1 out of 2,893

The General Hospital Corporation

patents

7. 1 out of 310

Health Research, Inc.

patents

8. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1985-2025

Loading Chart...

Areas of Expertise:

CD33 Antibodies

Immunogenicity Enhancement

Modular Self Assembly

Bispecific Antibodies

Multi-Specific Antibodies

T Cell Receptor-Like Antibodies

Radioimmunotherapy

Therapy-Enhancing Glucan

HLA-Restricted Antigen Binding

Monoclonal Antibodies

Anti-GD2 Antibodies

Immunoassay Techniques

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12441793 - CD33 antibodies and methods of using the same to treat cancer (2025-10-14),

2. 12364752 - Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans (2025-07-22),

3. 12343401 - Modular self assembly disassembly (SADA) technologies (2025-07-01),

4. 12195554 - Anti-polysialic acid antibodies and uses thereof (2025-01-14),

5. 11987642 - Bispecific HER2 and CD3 binding molecules (2024-05-21),

6. 11858993 - Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof (2024-01-02),

7. 11820832 - Bispecific HER2 and CD3 binding molecules (2023-11-21),

8. 11673957 - Anti-ROR2 antibodies (2023-06-13),

9. 11597764 - Anti-L1-CAM antibodies and uses thereof (2023-03-07),

10. 11583588 - Modular self assembly disassembly (SADA) technologies (2023-02-21),

11. 11555072 - A33 antibody compositions and methods of using the same in radioimmunotherapy (2023-01-17),

12. 11529371 - Anti-CD33 antibody agents (2022-12-20),

13. 11168150 - T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA (2021-11-09),

14. 11117964 - Anti-KIR3DL1 antibodies (2021-09-14),

15. 11091547 - Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof (2021-08-17),

Title: Nai-Kong V Cheung: Pioneering Innovator in Cancer Research

Introduction:

Nai-Kong V Cheung, a distinguished inventor in the field of oncology, hails from New York, NY, and is renowned for his exceptional contributions to cancer treatment. With an impressive portfolio of 44 patents, his groundbreaking work focuses on developing novel therapies for managing and treating various forms of cancer.

Latest Patents:

Among his recent patents is the innovative "Bispecific HER2 and CD3 binding molecules." These compositions function by targeting the HER2 receptor and CD3, facilitating T cell cytotoxicity to combat disorders like cancer. Additionally, Cheung's "Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex" offer promising prospects for detecting and treating diseases, notably colorectal cancer.

Career Highlights:

Cheung's remarkable career spans prestigious institutions such as the Memorial Sloan Kettering Cancer Center and the Sloan-Kettering Institute for Cancer Research. His relentless pursuit of developing effective cancer therapies has earned him recognition as a leading authority in the field.

Collaborations:

Throughout his career, Cheung has collaborated with esteemed professionals in oncology research. Notable coworkers include Hong Xu and Mahiuddin Ahmed, who have contributed significantly to his innovative projects. Their combined expertise has led to groundbreaking advancements in cancer treatment.

Conclusion:

In conclusion, Nai-Kong V Cheung's dedication to advancing cancer research through innovative patents underscores his unwavering commitment to improving patient outcomes. His pioneering work continues to inspire progress in the field of oncology, offering hope for the future of cancer treatment.

This text is generated by artificial intelligence and may not be accurate.